Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
On August9, 2017, Axsome Therapeutics,Inc. (the “Company”) issued a press release announcing its financial results for the three months ended June30, 2017 and an update on the Company’s operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit99.1.
In accordance with General Instruction B.2 of Form8-K, the information included in Item 2.02 of this Current Report on Form8-K (including Exhibit99.1 hereto), shall not be deemed “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
Item 2.02. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Description
|
|
99.1
|
Press release dated August9, 2017.
|
Axsome Therapeutics, Inc. ExhibitEX-99.1 2 a17-19963_1ex99d1.htm EX-99.1 Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2017 Financial Results NEW YORK,…To view the full exhibit click here
About Axsome Therapeutics,Inc. (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).